Therefore, vemurafenib monotherapy should not be used in patients with advanced melanoma with wild-type BRAF or RAS mutation (Heidorn et al., 2010; Poulikakos, Zhang, Bollag, & Shokat, 2010; Hatzivassiliou et al., 2010). Here, BRAF is linked to melanoma.